title: [Cytoreductive surgery in patients with stage IV ovarian carcinoma].
abstract: BACKGROUND
  The aim of this study is to evaluate the efficacy of cytoriductive surgical in females with ovarian carcinoma in advanced stadium, and to define the role of this surgical for the survival of females with hepatic metastases.
  
  
  METHODS
  This is a retrospective study. 164 females with ovarian cancer in IV stadium was examined. 64 females had hepatic metastasis. All patients had cytoriductive surgical.
  
  
  RESULTS
  The survival in the patients without hepatic metastasis was 38 months if the cytoreduction was very good; it was 18.3 months if there is residual disease. The survival in the patients with hepatic metastasis was 50.1 months if the cytoreduction was very good; it was 27 months if there is residual disease.
  
  
  CONCLUSIONS
  A very good surgical is very important for the survival of patients with ovarian cancer in advanced stadium. This is true also in the patients with hepatic metastases.
authors.affiliation: Istituto di Clinica Ostetrica e Ginecologica, Seconda Università degli Studi, Napoli.
authors.forename: G C
authors.initials: GC
authors.lastname: Balbi
authors.forename: R
authors.initials: R
authors.lastname: Compagna
authors.forename: R
authors.initials: R
authors.lastname: Musone
authors.forename: G
authors.initials: G
authors.lastname: Cirelli
authors.forename: R
authors.initials: R
authors.lastname: Sgambato
authors.forename: E
authors.initials: E
authors.lastname: Cassese
authors.forename: D
authors.initials: D
authors.lastname: Delli Ponti
authors.forename: M
authors.initials: M
authors.lastname: Passaro
authors.forename: R
authors.initials: R
authors.lastname: Zarcone
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D006801:Humans; D008875:Middle Aged; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D012189:Retrospective Studies; D015996:Survival Rate
vernacular_title: La chirurgia citoriduttiva nelle pazienti con carcinoma dell'ovaio allo stadio IV.